What is Diamedix?
Operating under the ImmunoVision brand, Diamedix has established itself as a cornerstone of the autoimmune research landscape since 1985. The company provides a comprehensive suite of high-precision diagnostic reagents, including purified antigens, monoclonal and polyclonal antibodies, and disease state plasma. By offering specialized services such as microtiter plate coating and custom assay development, the firm serves as a critical partner to pharmaceutical companies, contract research organizations, and academic institutions. As a member of the Calbiotech family, the company leverages an extensive international distribution network to ensure the seamless delivery of essential laboratory tools to researchers worldwide.
How much funding has Diamedix raised?
Diamedix has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Diamedix
PPP
Public-Private Partnership
What's next for Diamedix?
The infusion of capital signals a transition into a more aggressive growth phase, likely focused on scaling production capacity and enhancing R&D initiatives for next-generation diagnostic assays. Given the current late-stage funding context, Diamedix is expected to prioritize the optimization of its supply chain and the expansion of its custom purification services. By deepening its integration within the biotech ecosystem, the company aims to solidify its competitive advantage in the rapidly evolving autoimmune diagnostics market, ensuring that its portfolio of reagents remains at the forefront of clinical and laboratory standards.
See full Diamedix company page
